Navigation Links
FDA approves MyocondaR IND for MAP in Crohn's Disease

at which will now be an all-in-one oral capsule, the increased dosages and the new indication being sought.

"We are very pleased to have reached this key milestone in the development of MyocondaR. There is clearly a need for this type of therapy for the substantial subset of Crohn's Disease patients infected with MAP who are not well served by current therapies," said Patrick McLean, CEO of Giaconda "Giaconda is now another step closer to achieving its aim of bringing this product to market as soon as possible for the benefit of patients who are infected with MAP.

The development of MyocondaR is supported by a significant number of opinion leaders in the field". About Giaconda Limited Giaconda Limited is a biotechnology company involved in developing and licensing innovative and cost effective medical therapies in the field of gastroenterology. Giaconda's products are targeted towards the treatment of serious conditions that are not adequately addressed by any existing therapy. In this way, Giaconda's products are intended to satisfy these significant unmet medical needs of the gastrointestinal market. The Giaconda portfolio consists of five products, all of which are novel combinations of known compounds. Giaconda has two lead products, MyocondaR for the treatment of Crohn's Disease and HelicondaR for the treatment of resistant Helicobacter pylori infection. For more information please visit www.giacondalimited.com

About MyocondaR -
A Combination Antibiotic Therapy for the Treatment of Crohn's Disease MyocondaR, the Company's Anti-MAP therapy for the treatment of Crohn's Disease is a combination of three registered anti-mycobacterial drugs - rifabutin, clarithromycin and clofazimine. These three drugs are widely marketed world-wide for the treatment of mycobacterial and other infections. MyocondaR presents these three compounds in a specific patented combin
'"/>




Page: 1 2 3 4

Related medicine technology :

1. FDA approves IND on Lead Product M6G
2. ChemoCentryx Presents Positive Phase 2 Clinical Data for Traficet-EN in Crohns Disease at the Digestive Disease Week 2007 Conference
3. Enzo Biochem Individualized Oral Immune Regulation Therapy May Be Effective Approach to Treating Crohns Disease
4. UCB Presents Long-Term CImzia Data in Crohns Disease
5. New Analysis of Data Shows Treatment With Abbotts Humira (Adalimumab) Significantly Reduced Disease-Related Hospitalization for Patients with Crohns Disease
6. Appendicitis: Evolving Tools to Diagnose a Classic Disease
7. Non-Invasive Diagnostic Tests for Celiac Disease
8. Corgenix Reports New Clinical Data Correlating AtherOx Technology With Vascular Disease
9. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
10. Samaritans Alzheimers Drug Caprospinol Suggests Brain May be Able to Heal From Alzheimers Disease
11. BusinessWeek Article Highlights Promising Breakthrough Treatment for Advanced Coronary Artery Disease
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: FDA approves MyocondaR IND for MAP Crohn Disease
(Date:11/30/2008)...ec. 1 Abnormalities in ...in children with autism spectrum disorder by using...y presented today at the annual meeting of the Rad..., "Using MEG, we can record the tiny magnetic fi...aid Timothy Roberts, Ph.D., vice chair of research...
(Date:11/26/2008)...information density, automation and intelligent cl...trasound to an all new level , , CHICAGO, I...Healthcare ( www.siemens.com/healthcare ) highli...Scanner (ABVS)(1), the world,s first multi-use, a...4th Scientific Assembly and Annual Meeting of the ...
(Date:11/25/2008)...FRANCISCO, Calif., Nov. 25 Proteol...nt of novel therapeutics that target,protein degr..., today,announced that data from two ongoing Phas...eloma will be presented at the upcoming 50th Annua...ASH). Carfilzomib is the first in a new class,of...
(Date:11/24/2008)... Ill., and OSAKA, Japan, Nov. 24 T...y-owned subsidiary, Takeda Global Research & D...t the Arthritis Advisory Committee of the U.S. Foo...he FDA approve febuxostat for the treatment of hy... to zero in favor of approval, with one panel memb...
Breaking Medicine Technology:Brain Waves Show Sound Processing Abnormalities in Autistic Children 2Brain Waves Show Sound Processing Abnormalities in Autistic Children 3Siemens Introduces New Standard of Care for Breast Ultrasound 2Siemens Introduces New Standard of Care for Breast Ultrasound 3Siemens Introduces New Standard of Care for Breast Ultrasound 4Siemens Introduces New Standard of Care for Breast Ultrasound 5Proteolix to Present Clinical and Preclinical Data at the 50th Annual Meeting of the American Society of Hematology 2Proteolix to Present Clinical and Preclinical Data at the 50th Annual Meeting of the American Society of Hematology 3Arthritis Advisory Committee Recommends FDA Approval of Febuxostat for the Treatment of Hyperuricemia in Patients With Gout 2Arthritis Advisory Committee Recommends FDA Approval of Febuxostat for the Treatment of Hyperuricemia in Patients With Gout 3Bad News to Bad Bugs 3A Northern Antibiotics Develops Novel Polymyxins With Reduced Toxicity 2567 1Bad News to Bad Bugs 3A Northern Antibiotics Develops Novel Polymyxins With Reduced Toxicity 2567 2SuperGen Comments on Preliminary Efficacy Update on EORTC Phase 3 Trial of Dacogen 28R 29 Versus Supportive Care in Patients With Myelodysplastic Synd 2565 1SuperGen Comments on Preliminary Efficacy Update on EORTC Phase 3 Trial of Dacogen 28R 29 Versus Supportive Care in Patients With Myelodysplastic Synd 2565 2SuperGen Comments on Preliminary Efficacy Update on EORTC Phase 3 Trial of Dacogen 28R 29 Versus Supportive Care in Patients With Myelodysplastic Synd 2565 3SuperGen Comments on Preliminary Efficacy Update on EORTC Phase 3 Trial of Dacogen 28R 29 Versus Supportive Care in Patients With Myelodysplastic Synd 2565 4Pressure Cycling Technology 28PCT 29 Results in a Higher Yield of Proteins and in the Extraction of Proteins Not Previously Identified in Cancer Str 2563 1Pressure Cycling Technology 28PCT 29 Results in a Higher Yield of Proteins and in the Extraction of Proteins Not Previously Identified in Cancer Str 2563 2Pressure Cycling Technology 28PCT 29 Results in a Higher Yield of Proteins and in the Extraction of Proteins Not Previously Identified in Cancer Str 2563 3 Great Doctors Produce Great Results 28Healthcare Underwriters Group Mutual of Ohio Pays A Cash Dividend 29 3A Healthcare Underwriters Group Mut 23009 1 Great Doctors Produce Great Results 28Healthcare Underwriters Group Mutual of Ohio Pays A Cash Dividend 29 3A Healthcare Underwriters Group Mut 23009 2
...NGELES & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Ap...maceutical company focused on,the discovery and de...ay announced encouraging preclinical data of AV-41...nhibitor of EGFR/HER2 using,AVEO,s unique EGFR mut...he results from the preclinical study showed that ...
...r Presentation on April 17, 2007 at AACR, SAN DIEG...aceuticals, Inc. presented data from an in vitro s...promotes natural killer (NK),cell-mediated anti-tu...ysis of tumor cells and enhanced antibody-dependen...esentation at the Annual,Meeting of the American A...
Other Medicine Technology:AVEO Presents Preclinical Efficacy Data on AV-412, a Novel Oral,Tyrosine Kinase Inhibitor of EGFR/HER2 for EGFR Mutant and,Drug-Resistant Lung Cancer 2AVEO Presents Preclinical Efficacy Data on AV-412, a Novel Oral,Tyrosine Kinase Inhibitor of EGFR/HER2 for EGFR Mutant and,Drug-Resistant Lung Cancer 3AVEO Presents Preclinical Efficacy Data on AV-412, a Novel Oral,Tyrosine Kinase Inhibitor of EGFR/HER2 for EGFR Mutant and,Drug-Resistant Lung Cancer 4Anadys Reports Preclinical Data Showing ANA773 Promotes Anti-Tumor,Activity of Natural Killer Cells 2Anadys Reports Preclinical Data Showing ANA773 Promotes Anti-Tumor,Activity of Natural Killer Cells 3Anadys Reports Preclinical Data Showing ANA773 Promotes Anti-Tumor,Activity of Natural Killer Cells 4
(Date:12/2/2008).... 2 With the bright lights, sweet ...olidays may be an exciting time of year for any ch... especially with today,s tough economy. Whether i...tying their wallets, or spending hours traveling t...lax, and even less time to be alone and romantic w...
(Date:12/2/2008)...ologic-Treated Psoriasis Patients Will Double by 2...rces , , WALTHAM, Mass., Dec. 2 /PRNewswire...g research and advisory firms for pharmaceutical a...particularly Centocor/Janssen-Cilag,s Stelara and ...severe psoriasis drug market to more than double t...
(Date:12/2/2008)... New research estimates that 1500 l... with the highest risk-adjusted,mortality rates (...ery,performed as well as hospitals with the lowes...ity rate for women was higher than men regardless ...eased as performance declined.,The study ranked U...
(Date:12/2/2008)... 2 Mylan Inc. (NYSE: M...Mylan Pharmaceuticals Inc., have entered,into a s...Corp., Novartis,Corp. and Novartis International ...ion of Novartis, Femara(R). , Mylan,s Vice ...e very,pleased to have reached this agreement, wh...
Breaking Medicine News(10 mins):Health News:Jennie Finch Shares how to Fire up the Romance Despite the Demands of the Holidays 2Health News:Jennie Finch Shares how to Fire up the Romance Despite the Demands of the Holidays 3Health News:Biologic Drugs, Particularly Centocor/Janssen-Cilag's Stelara and Abbott/Eisai's Humira, will Drive the Psoriasis Drug Market to $5 Billion by 2017 2Health News:New Research Estimates 1500 Lives Could Be Saved Annually if the Lowest Performing Hospitals for Coronary Artery Bypass Graft Surgery Performed as Well as Top-ranking Hospitals 2Health News:New Research Estimates 1500 Lives Could Be Saved Annually if the Lowest Performing Hospitals for Coronary Artery Bypass Graft Surgery Performed as Well as Top-ranking Hospitals 3Health News:Mylan Announces Settlement Agreement with Novartis Related to Femara(R) First- to-File Opportunity 2
...be a promising treatment, according to a new study...ecial needle into the tumor. A current is then pas...sue and ablate, or eliminate, it. The research fin... also do not appear to have any serious complicati...
...n treatment for a specific type of testicular canc...pically treated by // removal of the testicle foll... of developing a second cancer in another organ up...ed more than 540 patients to receive a single cour...
...a new vaccine to children. Researchers found that ...nvasive pneumococcal disease (pneumonia or meningi... 2002, 14,730 fewer cases occurred among whites an...d with the average number in two prevaccine years,...
...ion that can cause death within days or even hours...ive care intended to keep patients alive long enou...r a donor organ becomes available for transplantat... die unless they receive a liver transplant. A bio...
Other Medicine News:
... laboratory and a worldwide leader in innovative l... extensive test menu of highly complex and unique ...Owned by the University of Utah, ARUP Laboratories...niversity teaching hospitals and children's hospit...
... laboratory and a worldwide leader in innovative l... extensive test menu of highly complex and unique ...Owned by the University of Utah, ARUP Laboratories...niversity teaching hospitals and children's hospit...
... laboratory and a worldwide leader in innovative l... extensive test menu of highly complex and unique ...Owned by the University of Utah, ARUP Laboratories...niversity teaching hospitals and children's hospit...
... laboratory and a worldwide leader in innovative l... extensive test menu of highly complex and unique ...Owned by the University of Utah, ARUP Laboratories...niversity teaching hospitals and children's hospit...
Medicine Products: